Compare · LQDA vs PULM
LQDA vs PULM
Side-by-side comparison of Liquidia Corporation (LQDA) and Pulmatrix Inc. (PULM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and PULM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LQDA is the larger of the two at $5.17B, about 1098.0x PULM ($4.7M).
- Both names hit the wire about 9 times in the past 4 weeks.
- LQDA has more recent analyst coverage (23 ratings vs 0 for PULM).
- Company
- Liquidia Corporation
- Pulmatrix Inc.
- Price
- -
- -
- Market cap
- $5.17B
- $4.7M
- 1M return
- -
- -1.47%
- 1Y return
- -
- -71.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2014
- News (4w)
- 9
- 9
- Recent ratings
- 23
- 0
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Pulmatrix Inc.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Latest LQDA
- H.C. Wainwright resumed coverage on Liquidia Technologies with a new price target
- Liquidia Technologies upgraded by Raymond James with a new price target
- Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
- Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by Liquidia Corporation
- Liquidia Corporation Reports Third Quarter 2026 Financial Results
- Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
- Chief Accounting Officer Boyle Dana sold $68,283 worth of shares (1,581 units at $43.19) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Business Officer Adair Jason sold $29,715 worth of shares (688 units at $43.19) as part of a pre-agreed trading plan (SEC Form 4)
- Liquidia Technologies upgraded by BTIG Research with a new price target
Latest PULM
- Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
- SEC Form 425 filed by Pulmatrix Inc.
- Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
- SEC Form 425 filed by Pulmatrix Inc.
- SEC Form 8-K filed by Pulmatrix Inc.
- SEC Form 424B3 filed by Pulmatrix Inc.
- SEC Form EFFECT filed by Pulmatrix Inc.
- Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
- SEC Form 425 filed by Pulmatrix Inc.
- SEC Form 425 filed by Pulmatrix Inc.